secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001387131-23-006742
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis Pharmaceuticals effects 1-for-70 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split effective 12:01 a.m. ET on May 22, 2023; shares begin trading split-adjusted same day.
- Ratio of 1-for-70 approved by board after shareholders authorized range of 1-for-2 to 1-for-100.
- Purpose: increase stock price to meet Nasdaq minimum $1.00 bid for 10 consecutive days by June 26, 2023.
- Split also a closing condition of the previously announced merger with DMK Pharmaceuticals.
- No change to authorized shares (200M common); CUSIP changes to 00547W 307; symbol remains ADMP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/0001387131-23-006742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/admp-8k_052223.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-006742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer